2020 American Transplant Congress
Impact of Rituximab and Apheresis Techniques in Acute Rejection Rates in ABO Incompatible Living Donor Kidney Transplant
*Purpose: ABO incompatibility (ABOi) is a widespread option of living kidney donor transplantation (LKDT). However, controversies in rejection, and death-censored graft survival rates are published,…2019 American Transplant Congress
Efficacy Of Rituximab Monotherapy On Anti-human Leukocyte Antigen Antibodies In Highly Sensitized Living Donor Kidney Transplant Patients.
*Purpose: We aim to examine the efficacy of Rituximab (RTX) monotherapy in reducing DSA in Highly Sensitised Living Donor Kidney Transplant (HS-LDKT) candidates and potentially…2019 American Transplant Congress
Variable Outcomes of Recurrent Autoimmune Diabetes Post Pancreas Transplant Treated with Rituximab
Washington University, St. Louis, MO
*Purpose: Demonstrate the outcomes of treatment with rituximab in patients with autoimmune diabetes after pancreas transplant.*Methods: We present the treatment response to rituximab in 3…2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…2018 American Transplant Congress
The Incidence of Polyomavirus-BK and Cytomegalovirus Infections in Renal Transplant Recipients Following Rituximab Administration
Northwestern Memorial Hospital, Chicago, IL.
Rituximab is an antibody that binds to the CD20 antigen on B cells resulting in rapid and prolonged depletion. At Northwestern Memorial Hospital, a single…2018 American Transplant Congress
Evaluation of FlowDSA Crossmatch for Detection of Donor-Specific HLA Antibodies
Background: Donor-specific HLA antibodies (DSA) are detected by different crossmatch techniques. Flow cytometric crossmatching (FCXM) is sensitive method, but it is subject to false (+)…2018 American Transplant Congress
CD19+ Cell Ratio as a Predictive Marker of Antibody Mediated Rejection in ABO Incompatible Kidney Transplantation
Background: Rituximab has been suggested to deplete B cells and decrease the possibility of antibody mediated rejection (AMR) in ABO-incompatible living kidney transplantation (ABO-ILKT). We…2018 American Transplant Congress
B-Cell Depletion with Rituximab Exacerbates Anti-Donor CD4+ T-Cell Responses in Patients with Donor-Specific Anti-Human Leukocyte Antigen Antibodies
Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Background: It has been reported that preformed donor-specific anti-human leukocyte antigen antibodies (DSAs) were associated with poor graft outcomes in kidney transplant recipients. To eliminate…2018 American Transplant Congress
Pretransplant Use of Rituximab is Associated with Posttransplant Malignancies Events and Death by Neoplasia in Incompatibility Living Donor Kidney Transplants
Introduction: Incompatibilities is a challenge in kidney transplantation. Potent immunosuppression approach based on desensitization protocols (DS) are usually needed; However, controversies in results and lack…2018 American Transplant Congress
Absence of Rejection in a Facial Allograft Recipient with a Postive Flow Crossmatch 24 Months after Induction with Rabbit Anti-Thymocyte Globulin and Anti-CD20+ Monoclonal Antibody
OBJECTIVE: Vascularized composite allograft (VCA) transplantation has become a feasible reconstructive option for patients with severe facial disfigurement. Short term patient and graft survival have…
American Transplant Congress abstracts